Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference
April 01, 2022 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product...
Immuneering Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
March 24, 2022 06:55 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product...
Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
March 10, 2022 06:30 ET
|
Immuneering Corporation
Lead Product Candidate, IMM-1-104, displays broad activity against a wide range of animal tumor models driven by MAPK pathway activating mutations including KRAS-G12D, KRAS-G12S, KRAS-G12C, NRAS-Q61R,...
Immuneering Announces Participation in March Investor Conferences
February 24, 2022 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Announces Participation in Upcoming Investor Conferences
January 24, 2022 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.
January 18, 2022 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event
January 06, 2022 16:10 ET
|
Immuneering Corporation
Preclinical Data Suggest IMM-1-104 May Offer Unique Therapeutic Advantage Compared with Binimetinib in NRAS Mutant Tumors Data to be discussed in Key External Expert event on January 6 2022, 5PM...
Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management
January 03, 2022 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Added to the Nasdaq Biotechnology Index
December 16, 2021 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Announces Participation in December Investor Conferences
November 18, 2021 06:35 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...